For decades, drug development operated on a single dominant logic: find a target protein, block its activity. The approval of the first PROTAC compound for breast cancer quietly dismantled that assumption, establishing that medicines can work by engineering molecular meetings — forcing two proteins together to trigger an entirely new biological outcome. This shift may ultimately expand the universe of druggable targets by an order of magnitude.
PROTACs, or proteolysis-targeting chimeras, function as molecular matchmakers, simultaneously binding a disease-causing protein and an E3 ubiquitin ligase enzyme. The forced proximity triggers ubiquitination and subsequent proteasomal degradation of the target — eliminating it rather than merely inhibiting it. The first clinically approved PROTAC, validated in breast cancer, demonstrated that this catalytic destruction mechanism could achieve target suppression at concentrations far below those required by conventional inhibitors. Beyond PROTACs, the emerging proximity pharmacology toolkit now includes molecular glues, bifunctional degraders targeting RNA, and compounds designed to recruit autophagy machinery — each exploiting induced proximity for distinct mechanistic ends.
The conceptual leap here is substantial and deserves careful contextualization. Traditional small-molecule inhibitors are constrained to proteins with well-defined binding pockets, leaving an estimated 80% of the human proteome historically considered "undruggable." Proximity-based strategies partially circumvent this limitation because they require only transient, lower-affinity interactions rather than deep catalytic-site engagement. However, critical translational challenges remain: tissue-specific E3 ligase expression varies considerably across cancer subtypes, creating unpredictable degradation efficiency; the pharmacokinetics of large bifunctional molecules complicate oral bioavailability; and resistance mechanisms, including target protein mutations that impair ternary complex formation, are already being documented clinically. This is an incrementally mature field rather than a mature one — the breast cancer approval is proof of concept, not proof of broad applicability. The next five years of clinical data across diverse tumor types will determine whether proximity pharmacology fulfills its considerable mechanistic promise.